P53 Modulators Targeting Y220C Pocket for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a critical need for small molecule reactivators that can specifically target the Y220C mutant p53 protein with high activity and low toxicity to restore its DNA binding ability and function, as this mutation is common in various cancers and current therapies are inadequate.
Innovation Solution
Development of compounds that bind to the Y220C pocket of the mutant p53 protein, stabilizing it and restoring its ability to bind to DNA at physiological temperatures, thereby reactivating its function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule reactivators are developed to target Y220C mutant p53, then the ability to restore DNA binding function is improved, but the challenge of achieving high specificity and low toxicity increases
Solution Approach 1:
The compound is designed to specifically target the Y220C mutation pocket in p53 by exploiting the unique structural features created by this specific mutation. The molecular structure includes functional groups that form specific interactions (hydrogen bonds, hydrophobic interactions) with residues surrounding the Y220C pocket, ensuring selective binding to the mutant form while sparing wild-type p53 and other proteins.
Solution Approach 2:
The small molecule compound acts as an intermediary that binds to the Y220C mutant p53 protein, stabilizing its structure and enabling it to regain DNA binding capability. The compound mediates the restoration of function by forming a ternary complex with the mutant protein and DNA, allowing the mutant p53 to perform its tumor suppressor function despite the mutation.
2Stability of the object's composition
If compounds are designed to bind to the Y220C pocket, then the stability of mutant protein is improved, but the complexity of achieving high binding specificity increases
Solution Approach 1:
The compound incorporates specific functional groups positioned to interact with unique structural features of the Y220C pocket, including the cysteine residue at position 220 and surrounding hydrophobic and polar residues. This localized targeting ensures that binding occurs selectively at the mutation site, stabilizing the protein structure without affecting other regions.
Solution Approach 2:
The molecular structure of the compound includes adjustable parameters such as substituent groups on aromatic rings, linker chain lengths, and functional group types that can be optimized to enhance binding affinity and specificity for the Y220C pocket. By systematically varying these parameters, the compound achieves optimal stability restoration while maintaining high specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively stabilize and reactivate the Y220C mutant p53 protein, allowing it to activate downstream pathways that inhibit cancer progression, providing a potential therapeutic approach for treating cancers associated with p53 malfunction.
Implementation Method 1
compounds, or pharmaceutically acceptable salts thereof, and compositions which bind to the Y220C pocket, stabilize the mutant protein and restore ability of the mutant protein to bind to DNA
Implementation Method 2
bind to the Y220C pocket, stabilize the mutant protein
Data Source
AI summary
Disclosed are p53 modulators represented by the following structural formula I:The variables in structural formula I are described herein. Also disclosed are method of treating cancer in a subject with the disclosed p53 modulators, particularly cancers with dysfunctional p53.